--- title: "EDAP TMS | 8-K: FY2026 Q2 Revenue: USD 13.2 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295838530.md" datetime: "2026-08-13T20:04:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295838530.md) - [en](https://longbridge.com/en/news/295838530.md) - [zh-HK](https://longbridge.com/zh-HK/news/295838530.md) generator: "portal-rs" --- # EDAP TMS | 8-K: FY2026 Q2 Revenue: USD 13.2 M Revenue: As of FY2026 Q2, the actual value is USD 13.2 M. EPS: As of FY2026 Q2, the actual value is USD -0.39. EBIT: As of FY2026 Q2, the actual value is USD -8.781 M. ### Second Quarter 2026 Results (Continuing Operations - HIFU Segment) #### Revenue Total revenue for the second quarter of 2026 was $13.2 million, a 39% increase compared to $9.5 million in the prior year period. #### Gross Margin Gross margin for the second quarter of 2026 was 55.6%, an increase from 51.1% in the prior year period, primarily due to better standard costs for the Focal One system and favorable absorption from higher production volumes. #### Operating Expenses Operating expenses were $15.4 million for the second quarter of 2026, up from $11.5 million in the prior year period, including approximately $0.8 million in one-time costs related to corporate rebranding, domestic filer transition, and discontinued operations classification. #### Operating Loss Operating loss was - $8.0 million for the second quarter of 2026, compared to - $6.6 million in the prior year period. #### Net Loss Net loss was - $14.4 million for the second quarter of 2026, compared to a net loss of - $6.4 million in the prior year period, mainly attributable to a - $5.5 million European Investment Bank warrant valuation impact. #### Operational Metrics U.S. Focal One procedures grew by 47% year-over-year. EDAP TMS S.A. sold 13 Focal One systems during the quarter, including 2 conversions from operating leases, representing a 44% year-over-year growth compared to 9 systems sold in the same period in 2025. The Focal One system installed base expanded to 184 units, with 96 in the U.S. and 88 internationally. The company launched its first commercial Focal One endometriosis program in Europe. An underwritten public offering for $40 million of gross proceeds was announced and expected to close on August 14, 2026. ### Six Months Ended June 30, 2026 Results (Continuing Operations - HIFU Segment) #### Total Revenue Total revenues for the six months ended June 30, 2026, were $24,796 thousand, up from $16,009 thousand for the same period in 2025. #### Segment Revenue Sales of goods were $17,782 thousand in 2026, compared to $10,185 thousand in 2025. Sales of RPPs & leases were $5,250 thousand in 2026, compared to $4,100 thousand in 2025. Sales of spare parts and services were $1,764 thousand in 2026, compared to $1,724 thousand in 2025. #### Gross Profit Gross profit was $13,300 thousand for the six months ended June 30, 2026, compared to $8,020 thousand for the same period in 2025. Gross profit as a percentage of net sales was 53.6% for the six months ended June 30, 2026. #### Operating Expenses Research & development expenses were - $4,784 thousand in 2026, compared to - $4,648 thousand in 2025. Selling, general & administrative expenses were - $24,574 thousand in 2026, compared to - $16,739 thousand in 2025. Total operating expenses were - $29,357 thousand in 2026, compared to - $21,388 thousand in 2025. #### Operating Loss Loss from operations was - $16,057 thousand for the six months ended June 30, 2026, compared to - $13,368 thousand for the same period in 2025. #### Net Loss Net loss for the six months ended June 30, 2026, was - $23,570 thousand, compared to - $13,850 thousand for the same period in 2025. #### Cash Flow Cash and cash equivalents totaled $21.5 million as of June 30, 2026. Operating cash flow for the six months ended June 30, 2026, was - $11,820 thousand, compared to - $10,827 thousand for the same period in 2025. Net cash generated by (used in) operating activities was - $6,663 thousand in 2026, compared to - $10,047 thousand in 2025. Net cash generated by (used in) investing activities was - $2,017 thousand in 2026, compared to - $2,917 thousand in 2025. Net cash generated by (used in) financing activities was $10,402 thousand in 2026, compared to - $1,198 thousand in 2025. ### Outlook EDAP TMS S.A. is reiterating its 2026 guidance for continuing operations (HIFU Segment). The company expects total revenue to be between $50.0 million and $54.0 million. This represents a projected year-over-year growth of 34% to 45%. ### Related Stocks - [FOCL.US](https://longbridge.com/en/quote/FOCL.US.md) ## Related News & Research - [FocalTherics slips 15%, prices $40M ADS offering at $4.75 per share](https://longbridge.com/en/news/295613788.md) - [FocalTherics (FOCL) Projected to Announce Quarterly Earnings on Thursday](https://longbridge.com/en/news/296439678.md) - [Edap TMS CFO Kenneth S. Mobeck buys 5,000 common shares for $23,750](https://longbridge.com/en/news/296088848.md) - [Insider Buying: FocalTherics (NASDAQ:FOCL) General Counsel Purchases $23,750.00 in Stock](https://longbridge.com/en/news/296095830.md) - [Edap TMS prices 8,425,000 ADS follow-on offering at $4.75 each](https://longbridge.com/en/news/295917314.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**